PT  - JOURNAL ARTICLE
AU  - Nicola J Gullick
AU  - David L Scott
TI  - Drug therapy of inflammatory arthritis
AID  - 10.7861/clinmedicine.12-4-357
DP  - 2012 Aug 01
TA  - Clinical Medicine
PG  - 357--363
VI  - 12
IP  - 4
4099  - http://www.rcpjournals.org/content/12/4/357.short
4100  - http://www.rcpjournals.org/content/12/4/357.full
SO  - Clin Med2012 Aug 01; 12
AB  - Inflammatory arthritis involves a diverse range of conditions in which an uncontrolled immune response occurs. A number of advances in assessment, diagnosis and treatment have been made in recent years. Drug therapies used in inflammatory arthritis aim to reduce symptoms and suppress inflammation, joint damage and disability. In rheumatoid arthritis (RA), immunosuppression is used in almost all patients, with an emphasis on early aggressive treatment to achieve clinical remission. This approach is less successful in spondylarthropathies, for which non-steroidal anti-inflammatory drugs remain first-line therapy. The use of biologic therapies has increased dramatically across a range of indications and has resulted in improved outcomes for patients. These agents are associated with an increased risk of infection, particularly tuberculosis in patients receiving tumour necrosis factor inhibitors. Alternative biologics have entered clinical practice for RA in recent years, and clinical trials using these agents, as well as novel non-biologic therapies, are in progress for RA and other conditions.